News & Updates
Showing Multidisciplinary articles
Showing
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
Sodium-glucose cotransporter 2 inhibitors (SGLT2is) consistently reduced the risk of serious hyperkalaemia (serum potassium [K+] ≥6.0 mmol/L) without increasing the risk of hypokalaemia (serum K+ ≤3.5 mmol/L) in individuals with type 2 diabetes (T2D) at high cardiovascular (CV) risk, or in those with chronic kidney disease (CKD), a meta-analysis has shown.
SGLT2is reduce serious hyperkalaemia risk in T2D, CKD patients
23 Jun 2022
Rare gene mutations predict prostate cancer relapse
Rare and deleterious germline mutations affecting inflammatory response and cellular signaling pathways associate strongly with the time to biochemical recurrence (BCR) after radical treatment in patients with prostate cancer (PrCa), according to a recent study.
Rare gene mutations predict prostate cancer relapse
23 Jun 2022
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
Upadacitinib treatment for atopic dermatitis (AD) may cause acne as a side effect, though this is usually only mild or moderate in severity and can be managed by topical intervention, reports a recent study.
Upadacitinib for atopic dermatitis may trigger mild, moderate acne
23 Jun 2022
HF risk: Time to rethink alcohol limits?
A moderate to high intake of alcohol appears to increase the risk of heart failure (HF) progression in individuals with pre-HF, according to a study presented at Heart Failure 2022.
HF risk: Time to rethink alcohol limits?
22 Jun 2022
Depression, sleep disturbance tied to urinary symptoms in men with LUTS
In men with lower urinary tract symptoms (LUTS), urinary symptom subdomains show an independent association with modifiable clinical variables such as sleep quality and depression at all time points, a study has found. However, these variables do not predict the degree of improvement in LUTS after assessment and treatment over the medium term.
